Get our Free Patent Expiration Newsletter

Serving hundreds of leading biopharmaceutical companies globally:

Accenture
McKinsey
AstraZeneca
Argus Health
Julphar
Cipla

Generated: September 17, 2019

DrugPatentWatch Database Preview

CLINICAL TRIALS PROFILE FOR ZEMPLAR

  Try a free trial


See Plans and Pricing

« Back to Dashboard

Clinical Trials for Zemplar

Trial ID Title Status Sponsor Phase Summary
NCT00048438 Safety and Efficacy of Zemplar Capsule in Reducing Serum IPTH Levels in Chronic Kidney Disease Subjects (Three Times Weekly) Completed Abbott Phase 3 The objective of this study is to determine whether paricalcitol is safe and effective compared to placebo in reducing elevated serum PTH levels in patients with chronic kidney disease.
NCT00048451 Safety and Efficacy of Zemplar Capsule in Reducing Serum iPTH Levels in Chronic Kidney Disease Subjects (Three Times Weekly) Completed Abbott Phase 3 The objective of this study is to determine whether paricalcitol is safe and effective compared to placebo in reducing elevated serum PTH levels in patients with chronic kidney disease.
NCT00048516 Safety and Efficacy of Zemplar Capsule in Reducing Serum iPTH Levels in Chronic Kidney Disease Subjects (Daily Dosing) Completed Abbott Phase 3 The objective of this study is to determine whether paricalcitol is safe and effective compared to placebo in reducing elevated serum PTH levels in patients with chronic kidney disease.
NCT00053378 A Study to Examine the Use of Zemplar to Increase Serum Calcium Levels in ICU Subjects Completed Abbott Phase 2 A study to determine the effect of Zemplar on the regulation of serum calcium levels and the need for administration of elemental calcium in hypocalcemic intensive care patients
NCT00053547 Safety and Effectiveness of Zemplar Injection in Decreasing iPTH Levels in Pediatric ESRD Subjects on Hemodialysis Completed Abbott Phase 4 The purpose of this study is to see if Zemplar, a vitamin D medication, safely and effectively decreases parathyroid hormone in children ages 2-20 with End Stage Renal Disease.
NCT00062699 Evaluate the Survival Benefits of Zemplar Versus Calcijex in Subjects w/ Stage V Chronic Kidney Disease on Hemodialysis Terminated Abbott Phase 4 To evaluate the survival benefit associated with Zemplar therapy as compared to Calcijex for the treatment of secondary hyperparathyroidism in subjects with Stage V chronic kidney disease on hemodialysis as measured by time to death.
>Trial ID >Title >Status >Phase >Summary

Subscribe to access the full database, or try a Free Trial

Clinical Trial Conditions for Zemplar

Condition Name

Condition Name for Zemplar
Intervention Trials
Secondary Hyperparathyroidism 7
Chronic Kidney Disease 6
Renal Insufficiency, Chronic 4
Kidney Disease 2
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Condition MeSH

Condition MeSH for Zemplar
Intervention Trials
Renal Insufficiency, Chronic 18
Kidney Diseases 18
Hyperparathyroidism, Secondary 10
Hyperparathyroidism 10
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Locations for Zemplar

Trials by Country

Trials by Country for Zemplar
Location Trials
United States 152
Greece 7
Malaysia 7
Poland 6
Italy 3
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Trials by US State

Trials by US State for Zemplar
Location Trials
California 12
New York 11
Florida 10
Texas 9
Illinois 8
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Progress for Zemplar

Clinical Trial Phase

Clinical Trial Phase for Zemplar
Clinical Trial Phase Trials
Phase 4 10
Phase 3 6
Phase 2/Phase 3 1
[disabled in preview] 17
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Status

Clinical Trial Status for Zemplar
Clinical Trial Phase Trials
Completed 26
Terminated 4
Not yet recruiting 2
[disabled in preview] 2
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Sponsors for Zemplar

Sponsor Name

Sponsor Name for Zemplar
Sponsor Trials
Abbott 22
National Cancer Institute (NCI) 2
Roswell Park Cancer Institute 2
[disabled in preview] 5
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Sponsor Type

Sponsor Type for Zemplar
Sponsor Trials
Industry 28
Other 19
NIH 2
[disabled in preview] 1
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Make Better Decisions: Try a trial or see plans & pricing

Serving hundreds of leading biopharmaceutical companies globally:

Covington
Chinese Patent Office
Express Scripts
Queensland Health
Teva
Julphar

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.